Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jan 31:16:1501110.
doi: 10.3389/fendo.2025.1501110. eCollection 2025.

Gestational diabetes mellitus and polycystic ovary syndrome, a position statement from EGOI-PCOS

Paola Quaresima  1 , Samuel H Myers  2 , Basilio Pintaudi  3   4 , Rosario D'Anna  3   5 , Michele Morelli  6 , Vittorio Unfer  3   7
Affiliations
Review

Gestational diabetes mellitus and polycystic ovary syndrome, a position statement from EGOI-PCOS

Paola Quaresima et al. Front Endocrinol (Lausanne). .

Erratum in

Abstract

Gestational diabetes mellitus is a worldwide health issue in pregnancy, posing a threat to both mother and child. One of the major risk factors for the development of gestational diabetes mellitus is polycystic ovary syndrome, primarily due to the biochemical hyperandrogenism and metabolic issues, commonly observed in these patients. In recent years, the Expert Group on Inositol in Basic and Clinical Research and on PCOS (EGOI-PCOS) has sought to better understand the pathogenesis behind polycystic ovary syndrome, in order to accurately diagnose and treat patients according to their individual needs. Through the scope of polycystic ovary syndrome, this position paper examines the characteristics of both conditions, and underlying biological mechanisms, before moving on to common treatment strategies to avoid or treat gestational diabetes mellitus in women with polycystic ovary syndrome.

Keywords: gestational diabetes mellitus; insulin; metformin; myo-inositol; polycystic ovary syndrome.

PubMed Disclaimer

Conflict of interest statement

SM and VU are employees of Lo.Li Pharma s.r.l, The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Similar articles

See all similar articles

Cited by

References

    1. Nakshine VS, Jogdand SD. A comprehensive review of gestational diabetes mellitus: impacts on maternal health, fetal development, childhood outcomes, and long-term treatment strategies. Cureus. (2023) 15:e47500. doi: 10.7759/cureus.47500 - DOI - PMC - PubMed
    1. Wang H, Li N, Chivese T, Werfalli M, Sun H, Yuen L, et al. . Idf diabetes atlas: estimation of global and regional gestational diabetes mellitus prevalence for 2021 by international association of diabetes in pregnancy study group&X2019;S criteria. Diabetes Res Clin Pract. (2022) 183:109050. doi: 10.1016/j.diabres.2021.109050 - DOI - PubMed
    1. Yu O, Christ JP, Schulze-Rath R, Covey J, Kelley A, Grafton J, et al. . Incidence, prevalence, and trends in polycystic ovary syndrome diagnosis: A United States population-based study from 2006 to 2019. Am J Obstet Gynecol. (2023) 229:39.e1–.e12. doi: 10.1016/j.ajog.2023.04.010 - DOI - PubMed
    1. Unfer V, Kandaraki E, Pkhaladze L, Roseff S, Vazquez-Levin MH, Laganà AS, et al. . When one size does not fit all: reconsidering pcos etiology, diagnosis, clinical subgroups, and subgroup-specific treatments. Endocr Metab Sci. (2024) 14:100159. doi: 10.1016/j.endmts.2024.100159 - DOI
    1. The Rotterdam ESHRE/ASRM‐sponsored PCOS consensus workshop group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (Pcos). Hum Reprod. (2004) 19:41–7. doi: 10.1093/humrep/deh098 - DOI - PubMed

LinkOut - more resources